Arcus Biosciences (RCUS)

Sell: $8.59|Buy: $22.00|Change: 0.30 (1.39%)

Company profile

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Address

3928 Point Eden Way
Hayward
CA
USA
94545


Telephone

+1 510 694-6200


Sector 

Healthcare


Previous key dates

NameKey Date
Arcus Biosciences Inc Fourth Quarter Earnings Conference Call for 20252026-02-25T13:05:00
Arcus Biosciences Inc Fourth Quarter Earnings Results for 20252026-02-25T00:00:00
Arcus Biosciences Inc Annual Report for 20252026-02-18T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-14T15:00:00
Citi’s 2025 Global Healthcare Conference2025-12-03T10:30:00
th Annual Evercore Healthcare Conference 20252025-12-02T16:40:00
Arcus Biosciences Inc Third Quarter Earnings Results for 20252025-10-28T00:00:00
Arcus Biosciences to Host Investor Event 20252025-10-06T10:00:00
Arcus Biosciences Morgan Stanley 23rd Annual Global Healthcare Conference 20252025-09-10T08:30:00
Arcus Biosciences HC Wainwright 27th Annual Global Investment Conference2025-09-09T08:00:00
Arcus Biosciences Citi’s Biotech Back to School Conference 20252025-09-03T11:15:00
Arcus Biosciences Inc Second Quarter Earnings Results for 20252025-08-06T00:00:00
Arcus Biosciences Inc Annual General Meeting for 20252025-06-10T08:30:00
Arcus Biosciences Inc First Quarter Earnings Conference Call for 20252025-05-06T16:30:00
Arcus Biosciences Inc First Quarter Earnings Results for 20252025-05-06T00:00:00
Barclays 27th Annual Global Healthcare Conference2025-03-13T08:00:00
Leerink's Global Healthcare Conference 20252025-03-12T08:00:00
Arcus Biosciences Inc Fourth Quarter Earnings Conference Call for 20242025-02-25T13:05:00
Arcus Biosciences Inc Fourth Quarter Earnings Results for 20242025-02-25T00:00:00
Arcus Biosciences Inc Annual Report for 20242025-02-18T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.